Chronic Pulmonary Aspergillosis: A Brief Review

Area of Science:

• Pulmonology
• Infectious Diseases
• Mycology

Background:

• Chronic Pulmonary Aspergillosis (CPA) is a destructive fungal lung infection.
• It primarily affects individuals with pre-existing or concurrent pulmonary conditions.
• Global prevalence is 42 per 100,000, but significantly lower in the US and Europe (<1 per 100,000).

Purpose of the Study:

• To raise awareness of CPA among healthcare practitioners.
• To provide an overview of risk factors, prevalence, and incidence.
• To discuss current diagnostic and treatment advancements for CPA.

Main Methods:

• Diagnosis is multi-factorial, requiring clinical presentation (>3 months), radiological findings, positive cultures, and serological tests.
• Global consensus guides diagnosis across diverse healthcare settings.
• Review of current literature on CPA risk factors, diagnosis, and treatment.

Main Results:

• CPA is underdiagnosed and often misdiagnosed due to low awareness and confounding comorbidities.
• Limited treatment options and complex drug interactions complicate patient management.
• Predictors of mortality and potential relapse/resistance are crucial for long-term survival.

Conclusions:

• Increased awareness is essential for earlier CPA identification.
• Further research is needed to improve understanding of prognosis and develop targeted therapies.
• Optimizing diagnosis and treatment strategies can improve outcomes for CPA patients.